Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer? - Archive ouverte HAL Access content directly
Journal Articles Cells Year : 2022

Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Abstract

Insulin-degrading enzyme (IDE) is a multifunctional protease due to the variety of its substrates, its various cellular locations, its conservation between species and its many non-proteolytic functions. Numerous studies have successfully demonstrated its implication in two main therapeutic areas: metabolic and neuronal diseases. In recent years, several reports have underlined the overexpression of this enzyme in different cancers. Still, the exact role of IDE in the physiopathology of cancer remains to be elucidated. Known as the main enzyme responsible for the degradation of insulin, an essential growth factor for healthy cells and cancer cells, IDE has also been shown to behave like a chaperone and interact with the proteasome. The pharmacological modulation of IDE (siRNA, chemical compounds, etc.) has demonstrated interesting results in cancer models. All these results point towards IDE as a potential target in cancer. In this review, we will discuss evidence of links between IDE and cancer development or resistance, IDE’s functions, catalytic or non-catalytic, in the context of cell proliferation, cancer development and the impact of the pharmacomodulation of IDE via cancer therapeutics.
Fichier principal
Vignette du fichier
IDE_Cancer_Lesire_et_al_Cells.pdf (1.06 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03657094 , version 1 (19-08-2022)

Identifiers

Cite

Laetitia Lesire, Florence Leroux, Rebecca Déprez-Poulain, Benoit Deprez. Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?. Cells, 2022, 11 (7), pp.1228. ⟨10.3390/cells11071228⟩. ⟨hal-03657094⟩
48 View
36 Download

Altmetric

Share

Gmail Facebook X LinkedIn More